At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02396 B&K CORP-B
To be listed 12-19 16:00:00
38.200
+0.000
0.00%
High38.200
Low38.200
Vol0.00
Open38.200
D1 Closing38.200
Amplitude0.00%
Mkt Cap4.49B
Tradable Cap3.17B
Total Shares117.66M
T/O0.00
T/O Rate0.00%
Tradable Shares83.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
New Stock Dark Pool | B&K CORP-B (02396) Surges Over 36% in Early Dark Trading, HK$2,760 Profit per Lot
Established in 2012, we are a biopharmaceutical company headquartered in China, dedicated to developing therapeutics, focusing on developing protein drugs for indications with medical needs and market opportunities. Our main focus is to discover, develop, and commercialize wound healing therapies, which are currently PDGF drugs. As of the last practical date, our pipeline contains ten candidate products, seven of which are PDGF drug candidates, including two core products, Pro-101-1 for treating burns and Pro-101-2 for treating sugar feet, which are rhPDGF-bB drugs.